← SynDRA
ICOTINIB
SynDRA canonical compound SYN0029889 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- EGFR
- BUB1
- CARS1
- GAK
- MAP3K1
- PIP4K2C
- RIPK2
- SLK
- STK10
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- EGFR ANTAGONIST
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABL1
- SYK
- PDGFRB
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- NQO2
- NLK
- NEK9
- NEK7
- NEK3
- PCYT1A
- PDXK
- NEK1
- PEBP1
- PRKAG1
- PRKACB
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIM2
- PIM1
- PHKG2
- PGRMC1
- PFKP
- NEK2
- NDUFA13
- PRKAR2A
- NAT10
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- icotinib hydrochloride
- Bpi-2009
- Icotinib hydrochloride
- Conmana
- Conmanna
- BPI-2009-H
- BPI 2009
- N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine
- CHEMBL2087361
- BPI2009
- 9G6U5L461Q
- N-(3-ethynylphenyl)-2,5,8,11-tetraoxa-15,17-diazatricyclo[10.8.0.014,19]icosa-1(12),13,15,17,19-pentaen-18-amine
- (1,4,7,10)Tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-
- N-(3-ethynylphenyl)-7H,8H,10H,11H,13H,14H-1,4,7,10-tetraoxacyclododeca[2,3-g]quinazolin-4-amine
- Lcotinib
- UNII-9G6U5L461Q
- icotinib,BPI-2009H
- ICOTINIB [WHO-DD]
- GTPL7641
- SCHEMBL5843603
- DTXSID20209952
- EX-A306
- HMS3651F12
- 4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline
- BCP21716
- BDBM50391089
- HY-15164A
- MFCD22124501
- NSC800770
- s2922
- ZINC43207566
- AKOS030231301
- CCG-264757
- DB11737
- NSC-800770
- SB16602
- NCGC00386224-06
- AC-32044
Look up ICOTINIB in the interactive SynDRA portal →